Kairos Pharma reported strong safety results from a Phase 2 trial of ENV-105 in mCRPC, with no serious toxicities seen in the first 10 patients.

Kairos Pharma Ltd (NYSE:KAPA) saw its stock jump 165% following the announcement of encouraging safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients battling metastatic ...

Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 ...

Kairos Pharma shares were higher as the company reported positive safety results from a clinical trial of ENV-105, or carotuximab, in patients with metastatic castration-resistant prostate cancer.

Trading to begin November 26, 2024 under ‘KAPA’LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (KAPA) today announced its approval to dual list its shares on Upstream, a ...

Kairos Pharma (KAPA) has selected IBN to spearhead its corporate communications efforts. Kairos Pharma’s development pipeline targets drug resistance and immune suppression, two critical ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with Cedars-Sin ...

LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (KAPA) today announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app ...

Kairos Pharma's ENV-105 aims to overcome resistance in CRPC and EGFR-mutant NSCLC, with key data releases expected in 2025. Explore more details here.

Kairos Pharma Ltd has a consensus price target of $8.5 based on the ratings of 4 analysts. The high is $12 issued by HC Wainwright & Co. on April 3, 2025.The low is $4 issued by Maxim Group on ...

Kairos Pharma reports positive results from phase 2 trial of ENV-105 in advanced prostate cancer: Los Angeles Thursday, July 17, 2025, 15:00 Hrs [IST] Kairos Pharma, Ltd., a clini ...

LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (KAPA) today announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app ...